Medical technology major,
Becton, Dickinson and Company
) inked an agreement for the installation of its BD Cato Workflow
Solution in The University of Texas MD Anderson Cancer Center. The
center will be the first healthcare institution in the U.S. to put
the BD Cato System into practice. It will incorporate the system
into its outpatient infusion pharmacies, including community-based
BD Cato Workflow Solution is an integrated software system that
draws on barcode technology and gravimetric verification to enhance
patient safety and optimize workflow efficiency in medication
preparation. The system is one of the several products available
under the company's BD Pharmacy Solutions.
This innovative system can help detect wrong drug dosages in real
time, thus preventing potential medical errors and avoid associated
costs. BD Cato Workflow Solution also assists in managing drug
remnants, optimizing drug utilization and reducing drug wastage.
By means of an automated documentation feature, BD Cato Workflow
Solution supports standardized practice, simplified workflow and
increased efficiency from medication preparation to delivery in
pharmacies. In addition, the system interfaces with Pharmacy IT
systems to pull in physician orders and allows dose queue
management within the preparation environment, thereby enhancing
patient safety and outcome.
In March last year, Becton, Dickinson acquired Austria-based Cato
Software Solutions, the manufacturer of cato and chemocato
softwares, a suite of comprehensive medication safety solutions.
This transaction reflects the company's continued focus on reducing
medication errors and improving workflow efficiencies.
The issue of medication errors is one of the top concerns on the
minds of healthcare providers today. With the implementation of the
BD Cato Workflow Solution, Becton, Dickinson intends to ensure that
a patient receives the right medication in the right dose.
Becton, Dickinson reported a 10.1% rise in fiscal
2014-second-quarter adjusted earnings per share to $1.53, beating
the Zacks Consensus Estimate by 3 cents. Revenues in the quarter
grew 3.6% (or 5.1% in constant currency) to $2,072 million, driven
by strong performance in the Medical segment and continued
improvement in the Biosciences segment. Revenues, however, fell shy
of the Zacks Consensus Estimate of $2,094 million.
For fiscal 2014, Becton, Dickinson raised its adjusted earnings per
share guidance to the range of $6.22 to $6.25 from the prior range
of $6.19 to $6.22. The revised earnings guidance represents
year-over-year growth of 7.0-7.5%.
On a foreign currency-neutral basis, adjusted earnings per share
are expected to grow between 10.0 and 10.5%, or 11.0 and 11.5%
excluding the incremental impact of the medical device tax. The
current Zacks Consensus Estimate of $6.25 coincides with the
upper-end of the guided range.
Becton, Dickinson continues to expect revenue growth in the range
of 4.0 to 5.0% for fiscal 2014. In constant currency, revenue
growth is expected between 4.5 and 5.0%.
Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical/dental supply industry include
Milestone Scientific Inc.
West Pharmaceutical Services, Inc.
). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BECTON DICKINSO (BDX): Free Stock Analysis
STERIS CORP (STE): Free Stock Analysis Report
WEST PHARM SVC (WST): Free Stock Analysis
MILESTONE SCI (MLSS): Get Free Report
To read this article on Zacks.com click here.